Payment overview · 2025
General Payments
$1,256.85
71 reported records · 21 companies
Healthcare provider profile · identity verified
Gustavo Ortega, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · TUCSON, AZ · NPI 1750644894
Verified facts
What the public records show
CMS Open Payments records show Gustavo Ortega, M.D. received $1,256.85 in general payments during 2025 across 71 reported records.
ABBVIE INC. accounted for 21.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 40 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Jardiance, Linzess, Mounjaro, Zenpep.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Synthroid by this doctor in 2024.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Zenpep by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Prolia by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 112 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $265.59 | 21.1% | 14 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $150.05 | 11.9% | 10 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $143.27 | 11.4% | 8 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $86.22 | 6.9% | 5 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $61.46 | 4.9% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $57.95 | 4.6% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $57.33 | 4.6% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $54.25 | 4.3% | 3 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $43.10 | 3.4% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $43.07 | 3.4% | 2 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $38.09 | 3.0% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $37.81 | 3.0% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $36.97 | 2.9% | 2 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $36.42 | 2.9% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $29.18 | 2.3% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $28.09 | 2.2% | 1 | 2025 |
| Soleno Therapeutics, Inc. | Unresolved — no canonical attribution shown | $25.42 | 2.0% | 1 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $18.44 | 1.5% | 1 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $14.94 | 1.2% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $14.73 | 1.2% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.47 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,256.85 | 71 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $120.44 | 7 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $106.56 | 7 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $92.02 | 5 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $92.02 | 5 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $92.02 | 5 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $81.22 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $63.93 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $63.93 | 3 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $61.46 | 4 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $57.95 | 4 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $57.33 | 3 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $55.10 | 3 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $52.99 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $51.25 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $51.25 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $43.49 | 3 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $43.10 | 2 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $43.10 | 2 | 2025 |
Source payment records
|
|||||
| ROTATEQ Normalized: rotateq |
Biological | Merck Sharp & Dohme LLC | $43.10 | 2 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $43.10 | 2 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $38.09 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $37.81 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $36.97 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $36.80 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $36.80 | 2 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $36.42 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $31.12 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $29.18 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $28.09 | 1 | 2025 |
Source payment records
|
|||||
| VYKAT XR Normalized: vykat xr |
Drug | Soleno Therapeutics, Inc. | $25.42 | 1 | 2025 |
Source payment records
|
|||||
| ENFLONSIA Normalized: enflonsia |
Drug | Merck Sharp & Dohme LLC | $22.12 | 1 | 2025 |
Source payment records
|
|||||
| VAXELIS Normalized: vaxelis |
Biological | Merck Sharp & Dohme LLC | $20.98 | 1 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $18.44 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $18.34 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $17.45 | 1 | 2025 |
Source payment records
|
|||||
| BYETTA Normalized: byetta |
Drug | AstraZeneca Pharmaceuticals LP | $16.65 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $15.01 | 1 | 2025 |
Source payment records
|
|||||
| Epclusa Normalized: epclusa |
Drug | Gilead Sciences, Inc. | $14.94 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $14.73 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $14.47 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 48 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 55 | exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
27 | 15 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
51 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
48 | 14 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
71 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
48 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
55 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
112 | 32 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
31 | 31 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 654 | 205 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 645 | 205 |
| Amlodipine Besylate | Amlodipine Besylate | 605 | 188 |
| Lisinopril | Lisinopril | 510 | 150 |
| Levothyroxine Sodium | Levothyroxine Sodium | 460 | 142 |
| Losartan Potassium | Losartan Potassium | 375 | 114 |
| Metformin Hcl | Metformin Hcl | 279 | 93 |
| Tamsulosin Hcl | Tamsulosin Hcl | 269 | 86 |
| Pantoprazole Sodium | Pantoprazole Sodium | 232 | 82 |
| Gabapentin | Gabapentin | 200 | 80 |
| Hydrochlorothiazide | Hydrochlorothiazide | 191 | 60 |
| Omeprazole | Omeprazole | 162 | 57 |
| Finasteride | Finasteride | 159 | 50 |
| Simvastatin | Simvastatin | 143 | 46 |
| Ozempic | Semaglutide | 142 | 27 |
| Allopurinol | Allopurinol | 130 | 39 |
| Montelukast Sodium | Montelukast Sodium | 130 | 44 |
| Furosemide | Furosemide | 122 | 43 |
| Eliquis | Apixaban | 112 | 32 |
| Metoprolol Tartrate | Metoprolol Tartrate | 104 | 36 |
| Escitalopram Oxalate | Escitalopram Oxalate | 100 | 39 |
| Alprazolam | Alprazolam | 95 | 27 |
| Pioglitazone Hcl | Pioglitazone Hcl | 95 | 29 |
| Atenolol | Atenolol | 93 | 25 |
| Tramadol Hcl | Tramadol Hcl | 92 | 20 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 86 | 26 |
| Metoprolol Succinate | Metoprolol Succinate | 84 | 31 |
| Fluticasone Propionate | Fluticasone Propionate | 82 | 37 |
| Famotidine | Famotidine | 81 | 33 |
| Alendronate Sodium | Alendronate Sodium | 78 | 27 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 76 | 49 |
| Lorazepam | Lorazepam | 73 | 29 |
| Metformin Hcl Er | Metformin Hcl | 73 | 23 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 71 | 17 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 71 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 70 | 30 |
| Sertraline Hcl | Sertraline Hcl | 69 | 22 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 65 | 21 |
| Carvedilol | Carvedilol | 64 | 23 |
| Donepezil Hcl | Donepezil Hcl | 64 | 25 |
| Meloxicam | Meloxicam | 64 | 23 |
| Ezetimibe | Ezetimibe | 60 | 20 |
| Paroxetine Hcl | Paroxetine Hcl | 60 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 58 | 21 |
| Trazodone Hcl | Trazodone Hcl | 56 | 22 |
| Mounjaro | Tirzepatide | 55 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 55 | 15 |
| Diclofenac Sodium | Diclofenac Sodium | 54 | 22 |
| Valsartan | Valsartan | 53 | 17 |
| Farxiga | Dapagliflozin Propanediol | 51 | 12 |
| Glipizide | Glipizide | 51 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 50 | 20 |
| Gemtesa | Vibegron | 50 | 14 |
| Oxycodone Hcl | Oxycodone Hcl | 49 | 12 |
| Xarelto | Rivaroxaban | 49 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 48 | 16 |
| Clonazepam | Clonazepam | 48 | suppressed |
| Jardiance | Empagliflozin | 48 | 14 |
| Ibandronate Sodium | Ibandronate Sodium | 47 | 20 |
| Potassium Chloride | Potassium Chloride | 47 | 19 |
| Irbesartan | Irbesartan | 46 | 14 |
| Celecoxib | Celecoxib | 45 | 20 |
| Buspirone Hcl | Buspirone Hcl | 44 | 15 |
| Temazepam | Temazepam | 43 | 17 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 43 | 17 |
| Mirtazapine | Mirtazapine | 42 | 19 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 40 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 39 | 22 |
| Spironolactone | Spironolactone | 39 | 16 |
| Prednisone | Prednisone | 37 | 31 |
| Symbicort | Budesonide/Formoterol Fumarate | 35 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 32 | 12 |
| Synthroid | Levothyroxine Sodium | 32 | suppressed |
| Bupropion Xl | Bupropion Hcl | 31 | 11 |
| Fenofibrate | Fenofibrate | 31 | 12 |
| Paxlovid | Nirmatrelvir/Ritonavir | 31 | 31 |
| Azelastine Hcl | Azelastine Hcl | 30 | 12 |
| Tresiba Flextouch U-100 | Insulin Degludec | 30 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 29 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 29 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | 13 |
| Lovastatin | Lovastatin | 27 | suppressed |
| Prolia | Denosumab | 27 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 26 | 19 |
| Linzess | Linaclotide | 26 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 26 | 18 |
| Cephalexin | Cephalexin | 25 | 23 |
| Terazosin Hcl | Terazosin Hcl | 25 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 25 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 24 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 24 | suppressed |
| Telmisartan | Telmisartan | 24 | 11 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 23 | suppressed |
| Myrbetriq | Mirabegron | 23 | suppressed |
| Pregabalin | Pregabalin | 23 | 12 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 21 | 15 |
| Ropinirole Hcl | Ropinirole Hcl | 21 | suppressed |
| Torsemide | Torsemide | 21 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 20 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 20 | suppressed |
| Methocarbamol | Methocarbamol | 20 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 19 | suppressed |
| Nifedipine Er | Nifedipine | 19 | suppressed |
| Ramipril | Ramipril | 19 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 19 | suppressed |
| Verapamil Er | Verapamil Hcl | 19 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Diazepam | Diazepam | 18 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 18 | suppressed |
| Latanoprost | Latanoprost | 18 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 18 | suppressed |
| Trulicity | Dulaglutide | 18 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 17 | suppressed |
| Dutasteride | Dutasteride | 17 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | 15 |
| Valacyclovir | Valacyclovir Hcl | 17 | 11 |
| Estradiol | Estradiol | 16 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Creon | Lipase/Protease/Amylase | 15 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 15 | suppressed |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 14 | suppressed |
| Memantine Hcl | Memantine Hcl | 14 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Ibuprofen | Ibuprofen | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Paxlovid (Eua) | Nirmatrelvir/Ritonavir | 11 | 11 |
| Sildenafil Citrate | Sildenafil Citrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,256.85 · 71 records | ABBVIE INC. | ABRYSVO, AIRSUPRA, BREZTRI, BYETTA, CAPVAXIVE, COMIRNATY, CREON, Cologuard Collection Kit, ENFLONSIA, EVENITY, Epclusa, FREESTYLE LIBRE 3, GARDASIL 9, JARDIANCE, KISUNLA, Kerendia, LINZESS, Leqembi, MOUNJARO, NURTEC ODT, OTEZLA, PREVNAR 20, QULIPTA, REPATHA, REXULTI, ROTATEQ, SHINGRIX, Senza, Tymlos, UBRELVY, VAXELIS, VAXNEUVANCE, VOQUEZNA, VRAYLAR, VYKAT XR, Veozah, XIFAXAN, ZAVZPRET, ZENPEP, ZEPBOUND | 15 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error